Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BENZODIAZEPINES WITH SLOWER RATE OF ACTION MAY HAVE LESS ABUSE POTENTIAL; SCHEDULING FOR EXISTING BENZOS RULED APPROPRIATE BY FDA HEARING PARTICIPANTS

Executive Summary

Slower acting benzodiazepines may have a lower abuse potential, John Roache, PhD, University of Texas, suggested at a Sept. 11 FDA public hearing on criteria for benzodiazepine scheduling in Washington, D.C. FDA convened a panel to examine whether data support differential scheduling of individual members of the benzodiazepine class, which have been collectively placed in Schedule IV since 1984.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel